{"name":"Bavarian Nordic","slug":"bavarian-nordic","ticker":"BAVA.CO","exchange":"OMX Copenhagen","domain":"bavarian-nordic.com","description":"Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.","hq":"Kvistgaard, Denmark","founded":1994,"employees":"1861","ceo":"Paul Chaplin","sector":"Vaccines / Biodefense","stockPrice":188.3,"stockChange":-10.1,"stockChangePercent":-5.09,"marketCap":"$2.3B","metrics":{"revenue":930884242.7387085,"revenueGrowth":-21.4,"grossMargin":48.1,"rdSpend":0,"netIncome":183446010.2632243,"cash":358318657.1567104,"dividendYield":0,"peRatio":12.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"IMVAMUNE patent cliff ($0.0B at risk)","drug":"IMVAMUNE","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"PROSTVAC patent cliff ($0.0B at risk)","drug":"PROSTVAC","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Chikungunya","genericName":"Chikungunya","slug":"chikungunya","indication":"Other","status":"marketed"},{"name":"IMVAMUNE","genericName":"IMVAMUNE","slug":"imvamune","indication":"Other","status":"marketed"},{"name":"MVA-BN-PRO","genericName":"MVA-BN-PRO","slug":"mva-bn-pro","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Chikungunya","genericName":"Chikungunya","slug":"chikungunya","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMVAMUNE","genericName":"IMVAMUNE","slug":"imvamune","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MVA-BN-PRO","genericName":"MVA-BN-PRO","slug":"mva-bn-pro","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Bavarian Nordic Reports Fourth Quarter and Full Year 2023 Results","summary":"The company reported a net loss of DKK 1.4 billion for the full year 2023, compared to a net loss of DKK 1.1 billion in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-11-21","type":"deal","headline":"Bavarian Nordic Signs Agreement with US Government for COVID-19 Vaccine","summary":"The company has signed an agreement with the US government to supply its COVID-19 vaccine, ABNCoV2, for use in the US.","drugName":"","sentiment":"positive"},{"date":"2023-09-12","type":"regulatory","headline":"FDA Grants Fast Track Designation to Bavarian Nordic's Chikungunya Vaccine","summary":"The FDA has granted fast track designation to the company's chikungunya vaccine, CHIKV VLP vaccine booster.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQeGpHbVE0emlZSTF5cG0tbzNRazhLMG1lNHhBZE5GTnphS1BGSjMwX0h4SURMbVVyc3c2dmNWUi1HTlBaRzBpYVo4UWt6SmFaNlVFdGFqRktqZzhTNzFTc3pURmJCR1RMWm5LY2liQ0F1QWFxcGt4UzJSQmMwWjQ5MkVpUFExWWxqUGtGMGJ6UFJXMUdLX2ZsWk1KTQ?oc=5","date":"2026-04-05","type":"pipeline","source":"Yahoo Finance","summary":"Does Bavarian Nordic (CPSE:BAVA) Offer Value After A 37% One Year Share Price Gain - Yahoo Finance","headline":"Does Bavarian Nordic (CPSE:BAVA) Offer Value After A 37% One Year Share Price Gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPdVdLMmJ1N045R0phNVFRWnN4LUxLeHVRelFfWU00ZWQ2anFmZUl5QWEtQm1lRW51ZkJwUkczNDF5V25RMlZVRVNBbURZVURVYTB2QmcxY3RyQjNuSmd2dHVxeUt5THZxeDVRenJnaGhYYjc1UzY3ZXVaREVQTG9Hb0RSLS1YMDVNTlJpTWMzb043WnVHemt2cg?oc=5","date":"2026-02-16","type":"pipeline","source":"Meyka","summary":"BAVA.CO Stock Today: February 15 – Travel Health +30%, 2026 Guide Lower - Meyka","headline":"BAVA.CO Stock Today: February 15 – Travel Health +30%, 2026 Guide Lower","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQRjE4bl9MZUhVUVEzVlFkdmxvUnJ0RGhOeVV4NnltTVNodS1fVkNEZGtXc213cUhjS0hDVlhnbXh6a3hLTkNkeWlndEVWelZJUkNaY1Z2M2VieUs2V1BQXzdOQnFyNVRsS1J0TGJOU3VhUHRzSkUtZlVRWVdVd3FhOG9fMmtfc21sdGlaT0UyWEFMb2d1RXlzc3RuUFFpRnRBdmFFQS1HWENiSUpkUFdHSzlvWkczSDhUc3dTRm5FT0hDQjEwYkVDdmJDV2dpM0x0bi0yS2h5akRlc05EYmNJ?oc=5","date":"2025-10-31","type":"pipeline","source":"Reuters","summary":"Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses - Reuters","headline":"Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNSWpySUU0S0pWbVhoLTRhbUZYZkUwUnJHWnRyX29iZUtOeGRZd1RZa3NwRGpZTlBiNU5xTk82WkdsVVE3ajJtNVNsa1hSam5WcTA0UWlvQ2tQSmNlN3pmaGN5Qk9lYlNxUHh4anNlaS1DUEVCWlFNVWQ3VjBzYW5EUGRCb1hERmxwd3k3VFp0Tk5fZGJLWGc3MFp4Ukx3cjdUQVkwYk50R1NkenZkaEF6NUtENGpCV2daQjBLVGQ2aFdkeFRlTFVzOVQxM291UlZLV1dJSTZ0Z0VxbHAtQlI1TlNB?oc=5","date":"2025-10-16","type":"pipeline","source":"Reuters","summary":"Nordic Capital-led consortium raises takeover price for Bavarian Nordic to $39 per share - Reuters","headline":"Nordic Capital-led consortium raises takeover price for Bavarian Nordic to $39 per share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOMTVBemg3c1oySU5LME5pWmo2bjYxNUxOU1l4b08xM29fOTc0c0JCbkx4bjRYenc5SmlQYkM3OUhpZ3FXaTBVVE9RZWhfNXV3Y29FaW1TRTNydTY1WFRvSFdXempzaGVXWXJqRkRyam5lSWJ4UnlWUWUtV2tRQ0ZZTmJXWUEwbXIwUWV4TTVBTW1JMEd1RnVDU3owQVg5Wnh4eFVlQVFRa3ZkenBGVjVJVVVUTUVSMUd4aVBGYk9JYW43Wk9tNHo0LUZENVlGVDUzRUFLNDBfcw?oc=5","date":"2025-08-22","type":"earnings","source":"Reuters","summary":"Bavarian Nordic beats revenue expectations, as launch of takeover bid nears - Reuters","headline":"Bavarian Nordic beats revenue expectations, as launch of takeover bid nears","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNeWROVk5qb0lORmpwMURFUFdvd1p3SjA0TVdaNUJ1VFJFUktBSXJPWGtvM3RlS2NuU0FjdElDRWE3WVdsSGd0elJSYUdtdlJnaERZbUxBcWoyTDl3VHpVWTBUYnE5aVUzZ3R4ZlAwSTZ3am1jZk1zYVpaalJYTVVwMTBaTzlQaFZ1UWo0WTdmZV9CYzZEMmVyZU5XR0RnWEtNX2x2bDNHVkJLQzlaSW05X3pVR2FhRzdBR04xU2pqVEhaZ0lGV2ZvV25Sb0xpR21YdUxxNGQ0MmlNU1diREE?oc=5","date":"2025-07-28","type":"pipeline","source":"Reuters","summary":"Nordic Capital, Permira make $3 billion offer for vaccine maker Bavarian Nordic - Reuters","headline":"Nordic Capital, Permira make $3 billion offer for vaccine maker Bavarian Nordic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQVlhzblFNNkpxbVV0QWtRcS1UbGJBS0dZRV9pb0ZTUDRQOWdwNlNPelhMTE5LWXRPSDBtdXRpdkE4SHNoODVnZTFOV1c4MlRYZUFQVnZTQzFVd0ZaVWhtdVZpS3Y5NzIwWlVCSzh4WFNOblM0elRoZ3FKTmRhRktJUVlIM1J2X2djc2pqajdfYmtNcVNJS2lrZHFiTjRnZTNWcGl2eTR5UzlmcXhNUTlmTXNyems4MzdCcEJGcl9uaW5TVDZyMHdPRA?oc=5","date":"2025-07-24","type":"pipeline","source":"Reuters","summary":"Vaccine maker Bavarian Nordic in takeover talks, shares rally - Reuters","headline":"Vaccine maker Bavarian Nordic in takeover talks, shares rally","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxONVdpSE01aDA4am9LNngtcFVacmtVSUlBemhjTTByQzZnck1ieXB6VnVadUlmU3RSWk5HSnlleGJieGxoOEVEQmViZ3ZseU1tdFZJOVZoeVBabDJZTXQ5X3N1QTZBTGVzS0tJdUxFa3IyZC1BbFlVc2pBOW5Qc0JzX2xxN0JrNldrRTlEV3FTMXBCXzQzZThBUmxFTE1sODNnbG0wR1Nta256dE41UlFoQ0ljLXZEZGVLbVBabHR0cHdhNHZPbklrWGt6UVZ0bDlCOWVpNXpHeXktazc4OWNGRQ?oc=5","date":"2025-04-01","type":"regulatory","source":"Reuters","summary":"US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine - Reuters","headline":"US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE01U1FvV05XbWJlTGx3Tk8wTGdOSEpWUm5KQ1F6b2J1NUc0NHdORjNRMUZWN2NRSXotbkFJeG52V1lIZWI5MW9Td3hrOEZzV21ULXVtSmxLUC1yeFNVdUhkRlFyekRvUFRkbjg0NTVTNGc5cGpRa2g4d0JJLW0?oc=5","date":"2024-08-19","type":"pipeline","source":"Yahoo Finance","summary":"Inside Bavarian Nordic: The $3.3 billion Danish pharma giant with the world’s only vaccine for mpox - Yahoo Finance","headline":"Inside Bavarian Nordic: The $3.3 billion Danish pharma giant with the world’s only vaccine for mpox","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQR0lscUFrX0tJdEJjdkRDOEhhQUhKT0M4ZFlhQUpNQ2c2SXkzY1F2SmxFeWlRd0V6X1UxVDZOaUxuaFp5NVhKU1ZkbE16WTRUUGYzVjI1UlZETVJselhyY0FqYTQtY3AzMUgzaWIwRHZOZUI5YjFqUTY5WDRUUGdHcXdDZjl0djR0R3BIWF9MVmNfeDhib3BTN0REd3lHOGNwVTRIMjN4TFAtMzR6R3VGV0lOb2p5Z1VhZDhV?oc=5","date":"2024-08-17","type":"pipeline","source":"Reuters","summary":"Bavarian Nordic to ramp up production of mpox vaccine - Reuters","headline":"Bavarian Nordic to ramp up production of mpox vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQRTZIYm1hSW9IQmZCNUtfa0pEUGRSUzFHZjJ2dTNSZGkxYzYyMWtlcGx4cml5QnF6bURiOWRxWTdqeW50TmtzUVkxNkVGODdYODdUWG1VV2UzM3BENWFjUmd6TTE0aHFnSFpKRmhOQ2hsUlFKa3R0aGNwS3FKeWlBTWRnLVFaN3lKVDlEc0VONTNTNkMxdmFSSUh0MThGSl9LemZMWm5rNzl0WjlqV05Sb2xWQWRaeTY3ZUdBYklaTkFFRHJSTk00TVdiZkE2M2E2TjlhRXp5U3c?oc=5","date":"2024-08-13","type":"pipeline","source":"Reuters","summary":"Bavarian Nordic to donate mpox vaccine doses following African emergency declaration - Reuters","headline":"Bavarian Nordic to donate mpox vaccine doses following African emergency declaration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPclRXRFBwYjlPem5kNGs5RUpNU0dBNllvTEdyRVJTWVFTQzZxMTZfaHhsRnZ3MXctcjRPQnVNT183Qy1fSnlmbW42dmhBMmxLOXVOSFVHbTgtdHlUZ0hnVGhoVWZYVUZQOXdaUHNoczFJZmRlRUFXdDVCa1pBbHMyY3NUUjU3OXh4bVkxTHBKbVY2UzgwbXFVdGhQRENCQzd4SVRPVlBVMlZiaGV2d3NralFWMEo?oc=5","date":"2022-08-19","type":"pipeline","source":"bloomberg.com","summary":"US Will Start Making Bavarian Nordic's Monkeypox Shot - bloomberg.com","headline":"US Will Start Making Bavarian Nordic's Monkeypox Shot","sentiment":"neutral"}],"patents":[{"drugName":"IMVAMUNE","drugSlug":"mva-bn","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"PROSTVAC","drugSlug":"mva-bn-pro","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"marketed":2,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","GlaxoSmithKline","Sanofi"],"therapeuticFocus":["Infectious Diseases","Cancer"],"financials":{"source":"yahoo_finance","revenue":976019236.7334399,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":976019236.7334399},{"period":"2024-12-31","value":893524396.57344},{"period":"2023-12-31","value":1103944309.7216},{"period":"2022-12-31","value":492513813.19232}],"grossProfit":476541624.14912,"grossProfitHistory":[{"period":"2025-12-31","value":476541624.14912},{"period":"2024-12-31","value":440612014.51392},{"period":"2023-12-31","value":719521637.17504},{"period":"2022-12-31","value":265931476.57088}],"rdSpend":121972470.41472,"rdSpendHistory":[{"period":"2025-12-31","value":121972470.41472},{"period":"2024-12-31","value":134822595.1424},{"period":"2023-12-31","value":348280631.8592},{"period":"2022-12-31","value":184934126.83008}],"sgaSpend":104919212.08768,"operatingIncome":282053414.65599996,"operatingIncomeHistory":[{"period":"2025-12-31","value":282053414.65599996},{"period":"2024-12-31","value":146899433.32479998},{"period":"2023-12-31","value":234868241.85536},{"period":"2022-12-31","value":-11064703.4784}],"netIncome":214991166.78272,"netIncomeHistory":[{"period":"2025-12-31","value":214991166.78272},{"period":"2024-12-31","value":154434873.89248},{"period":"2023-12-31","value":230593047.39135998},{"period":"2022-12-31","value":-54300753.31968}],"eps":12.6,"epsHistory":[{"period":"2024-12-31","value":12.6},{"period":"2023-12-31","value":19.2},{"period":"2022-12-31","value":-4.9},{"period":"2021-12-31","value":-7.4}],"cash":268000451.85152,"cashHistory":[{"period":"2025-12-31","value":268000451.85152},{"period":"2024-12-31","value":253774605.4976},{"period":"2023-12-31","value":230912710.01216},{"period":"2022-12-31","value":89944307.89568}],"totalAssets":2337607085.70688,"totalLiabilities":325830624.39616,"totalDebt":20456844.5888,"equity":2011776461.31072,"operatingCashflow":425472198.79872,"operatingCashflowHistory":[{"period":"2025-12-31","value":425472198.79872},{"period":"2024-12-31","value":304786507.20768},{"period":"2023-12-31","value":174947835.29343998},{"period":"2022-12-31","value":34397417.45472}],"capex":-212477164.8608,"capexHistory":[{"period":"2025-12-31","value":-212477164.8608},{"period":"2024-12-31","value":-263801695.05087999},{"period":"2023-12-31","value":-152782319.74719998},{"period":"2022-12-31","value":-215959846.128}],"freeCashflow":212995033.93792,"dividendsPaid":null,"buybacks":-23466050.02304,"employees":1861,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":-38023282.56576,"ebit":4747576.097279999,"ebitda":37878066.6368,"period":"2025-12-31","revenue":226804615.47072,"epsBasic":null,"netIncome":-46706225.96928,"rdExpense":28408081.034879997,"epsDiluted":null,"grossProfit":87735118.74176,"operatingIncome":3125503.2287999997},{"sga":64934342.12416,"ebit":183081021.51488,"ebitda":209802784.52864,"period":"2025-09-30","revenue":280569992.5184,"epsBasic":13.7,"netIncome":170827548.24128,"rdExpense":20820587.82528,"epsDiluted":13.7,"grossProfit":139600027.25952,"operatingIncome":180473387.36319998},{"sga":38984927.77024,"ebit":58605491.17504,"ebitda":85305839.13791999,"period":"2025-06-30","revenue":258153436.30271998,"epsBasic":4.5,"netIncome":56674697.68256,"rdExpense":45840245.079679996,"epsDiluted":4.5,"grossProfit":142812128.57727998,"operatingIncome":57986955.727359995},{"sga":39023224.75904,"ebit":37480559.52448,"ebitda":62594161.63711999,"period":"2025-03-31","revenue":210491192.4416,"epsBasic":2.7,"netIncome":34195146.828159995,"rdExpense":26903556.47488,"epsDiluted":2.7,"grossProfit":106394349.57056,"operatingIncome":40467568.33664},{"sga":53339889.6864,"ebit":118531212.42111999,"ebitda":144108286.25536,"period":"2024-12-31","revenue":327302635.59424,"epsBasic":null,"netIncome":120488266.70592,"rdExpense":31815887.78112,"epsDiluted":null,"grossProfit":196014149.104,"operatingIncome":110858371.63647999},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":0.9,"netIncome":null,"rdExpense":null,"epsDiluted":0.9,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":188.3,"previousClose":198.4,"fiftyTwoWeekHigh":244.8,"fiftyTwoWeekLow":162.55,"fiftyTwoWeekRange":"162.55 - 244.8","fiftyDayAverage":190.45,"twoHundredDayAverage":205.99,"beta":0.95,"enterpriseValue":1914801960.4874854,"forwardPE":17.2,"priceToBook":1.14,"priceToSales":2.42,"enterpriseToRevenue":2.06,"enterpriseToEbitda":8.75,"pegRatio":0,"ebitda":218761303.68471038,"ebitdaMargin":23.5,"freeCashflow":-79079098.90293759,"operatingCashflow":368458464.2831974,"totalDebt":21771917.540433917,"debtToEquity":1.1,"currentRatio":6.47,"returnOnAssets":3.5,"returnOnEquity":9.7,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":268.33,"targetHighPrice":280,"targetLowPrice":250,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":31.1,"sharesOutstanding":76488104,"floatShares":76353485,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":15.1,"epsForward":10.92,"revenuePerShare":75.42,"bookValue":164.47,"officers":[{"age":58,"name":"Dr. Paul John Chaplin MSc, Ph.D.","title":"CEO & President"},{"age":60,"name":"Mr. Henrik  Juuel M.Sc.","title":"CFO & Executive VP"},{"age":57,"name":"Mr. Russell  Thirsk M.Sc.","title":"Executive VP & COO"},{"age":null,"name":"Mr. Rolf Sass Sorensen","title":"Vice President of Investor Relations"},{"age":null,"name":"Ms. Nicole  Seroff","title":"Vice President Corporate Communications"},{"age":58,"name":"Mr. Jean-Christophe  May M.B.A., Pharm.D.","title":"Executive VP & Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"http://www.bavarian-nordic.com/investor.aspx","website":"https://www.bavarian-nordic.com","phone":"45 33 26 83 83"}}